The Effects of the Levosimendan Metabolites OR-1855 and OR-1896 on Endothelial Pro-Inflammatory Responses

The calcium sensitizer levosimendan is used for the treatment of acute decompensated heart failure. A small portion (4–7%) of levosimendan is metabolized to the pharmacologically active metabolite OR-1896 via the inactive intermediate OR-1855. In addition, levosimendan has been shown to exert positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kipka, Hannah, Schaflinger, Rebecca, Tomasi, Roland, Pogoda, Kristin, Mannell, Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045601/
https://www.ncbi.nlm.nih.gov/pubmed/36979897
http://dx.doi.org/10.3390/biomedicines11030918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045601/
https://www.ncbi.nlm.nih.gov/pubmed/36979897
http://dx.doi.org/10.3390/biomedicines11030918

Ejemplares similares